Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Citi
McKinsey
McKesson
Johnson and Johnson
Merck
Healthtrust
Covington

Generated: August 20, 2018

DrugPatentWatch Database Preview

KARBINAL ER Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Karbinal Er patents expire, and what generic alternatives are available?

Karbinal Er is a drug marketed by Tris Pharma Inc and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in KARBINAL ER is carbinoxamine maleate. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the carbinoxamine maleate profile page.

Drug patent expirations by year for KARBINAL ER
Pharmacology for KARBINAL ER
Synonyms for KARBINAL ER
(Z)-2-butenedioic acid; 2-[(4-chlorophenyl)-(2-pyridinyl)methoxy]-N,N-dimethylethanamine
(Z)-but-2-enedioic acid; 2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N,N-dimethyl-ethanamine
(Z)-but-2-enedioic acid; 2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
(Z)-but-2-enedioic acid;2-[(4-chlorophenyl)-pyridin-2-ylmethoxy]-N,N-dimethylethanamine
121366-99-2
2-((4-chlorophenyl)-2-pyridinylmethoxy)-n,n-dimethyl-ethanamin(z)-2-bute
2-((4-chlorophenyl)(pyridin-2-yl)methoxy)-N,N-dimethylethan-1-amine maleate
2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine bimaleate
2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine maleate
2-(p-Chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)pyridine maleate (1:1)
2-[(4-chlorophenyl)-(2-pyridyl)methoxy]-N,N-dimethyl-ethanamine; maleic acid
2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine (2Z)-but-2-enedioate
2-[(4-chlorophenyl)(pyridin-2-yl)methoxy]-N,N-dimethylethanamine maleate
2-[(4-Clorophenyl)-2-pyridinylmethoxy]-N,N-dimethylethanamine Maleate Salt
2-[p-Chloro-.alpha.-[2-(dimethylamino)ethoxy]benzyl]pyridine bimaleate
2-[p-Chloro-.alpha.-[2-(dimethylamino)ethoxy]benzyl]pyridine maleate
2-[p-Chloro-alpha-[2-(dimethylamino)ethoxy]benzyl]pyridine maleate
3505-38-2
486-16-8 (Parent)
A822512
AC-5508
AC1NR00M
AKOS015962162
Allergefon maleate
AN-10927
Arbinoxa
C16H19ClN2O.C4H4O4
C20H23ClN2O5
Carbinoxamine hydrogen maleate
CARBINOXAMINE MALEATE
Carbinoxamine maleate (JAN/USP)
Carbinoxamine maleate [USAN:JAN]
Carbinoxamine maleate [USP:JAN]
Carbinoxamine maleate salt
Carbinoxamine maleate salt, analytical standard
Carbinoxamine maleate, United States Pharmacopeia (USP) Reference Standard
CARBINOXAMINE; MALEIC ACID
CAS-3505-38-2
CCG-40113
CHEBI:31353
CHEMBL1200974
Ciberon
Clistin (TN)
Clistin maleate
Clistin-D
Clistine Maleate
Cliston
component of Clistin-D
CPD001496929
CS-8018
D01336
DSSTox_CID_27805
DSSTox_GSID_47828
DSSTox_RID_82573
DTXSID0047828
EINECS 222-498-0
Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-, (2Z)-2-butenedioate (1:1)
Ethanamine, 2-((4-chlorophenyl)-2-pyridinylmethoxy)-N,N-dimethyl-, (Z)-2-butenedioate (1:1)
Ethanamine, 2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N, N-dimethyl-, (Z)-2-butenedioate
Ethanamine,N-dimethyl-, (Z)-2-butenedioate (1:1)
GP7553
HE016982
Hislosine
Histine sirup
HMS1570B03
HMS1920I21
HMS2091A04
HMS2097B03
HMS3259G22
HMS502I21
HY-B1589A
Karbinal er (TN)
Lergefin
LS-131077
MFCD00082461
MolPort-003-666-137
NC00602
NCGC00095302-01
NCGC00166141-01
NCGC00166141-06
NSC 62362
NSC-62362
NSC-756670
NSC62362
NSC756670
p-Carbinoxamine maleate
Paracarbinoxamine maleate
Pharmakon1600-01500161
Polistin T-caps
Polistine T-caps
Prestwick_238
Pyridine, 2-(p-chloro-alpha-(2-(dimethylamino)ethoxy)benzyl)-, maleate (1:1)
s4696
SAM002548927
SAM002589920
SCHEMBL97703
SPECTRUM1500161
SR-01000736676
SR-01000736676-2
T721
Tox21_112336
Tox21_112336_1
V1556
WLN: QV1U1VQ -C &621
Ziriton

US Patents and Regulatory Information for KARBINAL ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Tris Pharma Inc KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for KARBINAL ER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,675,704 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
9,198,864 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
9,549,989 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
8,202,537 Modified release formulations containing drug-ion exchange resin complexes ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Federal Trade Commission
Accenture
US Army
QuintilesIMS
Queensland Health
Moodys
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.